Friday, 22 Jun 2018

You are here

Suspending Methotrexate for Influenza Vaccination

Vaccinating our rheumatoid arthritis patients against influenza every year is a safety priorty. However immunosuppressive therapies pose a challenge to vaccine administration as their use can hamper vaccine immunogenicity. The current issue of Annals of Rheumatic Disease published the findings of a prospective single-center randomized parallel group study looking at the effects of temporarily discontinuing methotrexate on response to the seasonal trivalent influenza vaccine in RA patients living in Seoul, Korea.

Patients who were on a stable dose of methotrexate were randomized into one of 4 groups: 1) continued methotrexate, 2) held methotrexate for 4 weeks before vaccination, 3) held methotrexate for 2 weeks before and 2 weeks after vaccination, and 4) held methotrexate for 4 weeks after vaccination. Patients could continue taking prednisolone equivalent up to 10 mg daily. The primary endpoint was satisfactory vaccine response after 4 weeks, defined by a ≥4-fold increase in haemaglutination inhibition (HI) antibody titers. 

The per-protocol population included 199 patients across the four groups. They found that group 3 achieved higher satisfactory vaccine response against all 3 viral antigens compared to group 1 (51.0% vs 31.5%, p=0.044). The vaccine was well tolerated in all patients. 30% experienced an RA flare which was more common in groups 2 and 3 but not of statistical significance. 

While the authors were unable to enroll enough patients to meet their target due to short enrollment period (thus rendering this study underpowered), it still has important clinical implications and suggests that temporarily discontinuing methotrexate 2 weeks before and 2 weeks after influenza vaccination can significantly improve vaccine immunogenicity. It is unclear if the same result can be expected for patients with active RA. Also, further studies are needed to determine if this effect will result in lower incidence of influenza. 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

NSAID Use Around Conception Increases Miscarriage Risk

A study from the American Journal of Obstetrics & Gynecology analyzed pregnant women from the Kaiser Permanente healthcare system and compared newly pregnant women who took non-steroidal anti-inflammatory drugs or acetaminophen or neither showed that using NSAIDs around conception carried a more than four-fold higher risk of early miscarriage. (Citation source: http://bit.ly/2tqNWN6)

Could Measuring Drug Levels with TNF Treatment Hurt Your Patients?

Our colleagues in gastroenterology measure drug levels with certain biologics used in inflammatory bowel disease in order to increase the dose for optimal benefit if the patient has a low trough level (i.e. targeting drug level).

There have been GI trials with T2T with drug levels but they are not always suggesting that the strategy is superior to usual care. Also, this is really not a common practice in rheumatology.

Methotrexate Update

I was delighted to see that investigators presenting work at EULAR 2018 haven’t lost interest in our old friend methotrexate, with a number of abstracts examining issues of safety, dose and route of administration.

Low incidence of methotrexate induced liver abnormalities

Cancer Therapies Inducing Immune-Related Adverse Events (irAEs)

Recent shifts in the cancer treatment paradigm towards immune therapies has led to wide implementation of the novel immune check point inhibitors (ICI) in the treatment of multiple types of advanced cancer.

While being quite effective in oncology, these checkpoint inhibitors have led to the emergence of a quite unique spectrum of rheumatologic conditions presented under the umbrella of immune-related adverse events (irAEs).

Tobacco Associated Deaths in the USA

JAMA Internal Medicine reports that in the USA, those who smoke cigar, pipe, or cigarette have a significant overall  mortality risk, and a much highers cancer mortality risk compared to nonsmokers.

The National Longitudinal Mortality Study collected baseline survey data from 1985 through 2011 and included 357,420 participants reporting on their use of cigar, pipes, or cigarettes.